1. Scrip
  2. >>Business
  3. >>Deals

Recent Tech Transfer Deals, October 2012

 
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant

START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

Arch Biopartners gets option to University of Alberta's IBS diagnostic technology

Public Canadian biotech Arch Biopartners Inc. received a one-year option to acquire intellectual property relating to an irritable bowel...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Chiesi Moves Into Rare Disease Gene Therapy Under Pact With Arbor

 
• By Joseph Haas

Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.

Deal Watch: Clywedog, Barinthus To Merge With Focus On Diabetes, Celiac Disease

 
• By Joseph Haas

Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.

More from Business

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.

Finance Watch: Job Cuts At Takeda, Bolt, Innate, X4 As Strategies Shift

 
• By Mandy Jackson

Restructuring Edition: Takeda’s shift away from cell therapies will impact 137 employees. Meanwhile, Bolt is cutting its workforce by 50% to extend its cash runway into 2027, Innate’s staffing will drop by 30% and X4 will halve its workforce under a restructuring plan.